

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **POSITIVE PROFIT ALERT**

This announcement is made by Ascletis Pharma Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the unaudited consolidated management account figures of the Group for the six months ended June 30, 2023, the Group expects to record (i) a total revenue ranging from RMB46.0 million to RMB47.0 million for the six months ended June 30, 2023, representing an increase of approximately 20.4% to 23.0% from approximately RMB38.2 million for the six months ended June 30, 2022; and (ii) a net loss attributable to the owners of the Company ranging from RMB14.0 million to RMB22.0 million for the six months ended June 30, 2023, representing a decrease of approximately 84.1% to 75.0% as compared to that for the six months ended June 30, 2022 (for the six months ended June 30, 2022: approximately RMB88.0 million). The Board considers that the increase in total revenue was mainly attributable to the increase in revenue generated from sales of ritonavir and the decrease in net loss attributable to the owners of the Company was primarily a result of such increase in total revenue and the effective cost control measures.

As at the date of this announcement, the Company is still in the process of finalizing its consolidated financial results of the Group for the six months ended June 30, 2023. The information contained in this announcement is based solely on the Group’s unaudited consolidated management account figures for the six months ended June 30, 2023 and is subject to finalization and other potential adjustments, if any, and has not been reviewed or confirmed by the Group’s auditors or the audit committee of the Board.

Shareholders and potential investors of the Company should refer to the Group’s interim results announcement for the six months ended June 30, 2023, which is expected to be published in August 2023.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People's Republic of China  
July 18, 2023

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*